<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Peutz-Jeghers syndrome: Clinical manifestations, diagnosis, and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Chung, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Thomas Lamont, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Peutz-Jeghers syndrome (PJS) is an autosomal dominant syndrome characterized by multiple hamartomatous polyps in the gastrointestinal tract, mucocutaneous pigmentation, and an increased risk of gastrointestinal and nongastrointestinal cancer [<a href="#rid1">1-3</a>].</p><p>This topic will review the genetic basis, clinical manifestations, and diagnosis of PJS. The management of PJS and other familial hamartomatous polyposis syndromes of the gastrointestinal tract (eg, juvenile polyposis, Cowden syndrome, and Bannayan-Riley Ruvalcaba syndrome) are discussed in detail, separately [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/2594.html" rel="external">"Overview of colon polyps"</a> and  <a class="medical medical_review" href="/d/html/15805.html" rel="external">"Juvenile polyposis syndrome"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY AND GENETICS</span><span class="headingEndMark"> — </span>Peutz-Jeghers syndrome (PJS) is rare with an estimated prevalence of 1:8000 to 1:200,000 births [<a href="#rid5">5</a>]. Males and females are equally affected.</p><p>PJS is an autosomal dominant disorder that is most often due to germline mutations in the <em>STK11 </em>(<em>LKB1) </em>gene<em> </em>encoding a serine threonine kinase mapped to chromosome 19p13.3 [<a href="#rid6">6-8</a>]. Germline mutations in <em>STK11,</em> a designated tumor suppressor gene in combination with an acquired genetic defect of the second <em>STK11</em> allele in somatic cells, are responsible for the clinical manifestations of PJS [<a href="#rid7">7-10</a>]. PJS has a high penetrance of over 90 percent by the age of 30 years, but 10 to 20 percent of individuals with PJS have no family history and are presumed to have PJS due to <em>de novo</em> mutations [<a href="#rid11">11</a>].</p><p><em>STK11 </em>is a tumor suppressor that regulates the activity of AMP-activated protein kinase (AMPK) family members to control multiple cellular processes including cell polarity, metabolism, and apoptosis [<a href="#rid12">12</a>]. In addition, deletion of <em>STK11</em> specifically in T-cells has been shown to promote the development of gastrointestinal polyps in an animal model, indicating a provocative role for the immune system in tumor formation [<a href="#rid13">13</a>].  </p><p>Mutations in <em>STK11</em> are detected in only 50 to 80 percent of families with PJS, suggesting that there is a second PJS gene locus [<a href="#rid9">9,14-17</a>].</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The two characteristic manifestations of Peutz-Jeghers syndrome (PJS) are pigmented mucocutaneous macules and multiple hamartomatous gastrointestinal polyps. Individuals with PJS are also at an increased risk for both gastrointestinal and extra-intestinal cancers.</p><p class="headingAnchor" id="H435868361"><span class="h2">Mucocutaneous pigmentation</span><span class="headingEndMark"> — </span>Mucocutaneous pigmented macules (melanin spots) are present in more than 95 percent of individuals with PJS and are caused by pigment-laden macrophages in the dermis. They are typically flat, blue-gray to brown spots 1 to 5 mm in size. These pigmented macules most commonly occur on the lips and perioral region (94 percent), palms of the hands (74 percent), buccal mucosa (66 percent), and soles of the feet (62 percent)  (<a class="graphic graphic_picture graphicRef80815" href="/d/graphic/80815.html" rel="external">picture 1</a>) [<a href="#rid18">18</a>]. They may also be seen on the nose, perianal area, and genitals, and rarely in the intestines. Mucocutaneous pigmentation usually occurs during the first one to two years of life, increases in size and number over the ensuing years, and finally fades after puberty with the exception of those on the buccal mucosa. Malignant transformation is extremely rare.</p><p>Mucocutaneous pigmented macules in individuals with PJS may be confused for ephelides (freckles). However, ephelides are typically sparse near the nostrils and mouth, are absent at birth, and never appear on the buccal mucosa. The mucocutaneous pigmented macules, although sensitive for PJS, are not specific and may be associated with other syndromes. (See <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h2">Hamartomatous polyps</span><span class="headingEndMark"> — </span>Gastrointestinal hamartomatous polyps are present in most patients with PJS. Although polyps most commonly occur in the small bowel (60 to 90 percent) and more specifically in the jejunum, they can be found throughout the gastrointestinal tract including the stomach (15 to 30 percent) and colon (50 to 64 percent) [<a href="#rid18">18</a>].</p><p>Gastrointestinal polyps develop in the first decade of life and most patients become symptomatic between the ages of 10 and 30. Hamartomatous polyps may also occur outside the gastrointestinal tract, including the renal pelvis, urinary bladder, lungs, and nasopharynx.</p><p>Although 50 percent of patients are asymptomatic at the time of diagnosis, individuals with PJS can present with obstruction caused by intussusception or occlusion of the gastrointestinal lumen by the polyp, abdominal pain caused by infarction, anemia from acute or chronic bleeding, or extrusion of the polyp through the rectum. Up to 69 percent of patients experience an intussusception during their lifetime, most often in the small intestine [<a href="#rid18">18-22</a>].</p><p>On gastrointestinal endoscopy, the Peutz-Jeghers (PJ) polyps have no major distinguishing features, and may be sessile, pedunculated, or lobulated. The number of polyps ranges from 1 to more than 20 per segment of bowel, although some patients have solitary lesions. The size of the polyps ranges from 0.1 to more than 5 cm in diameter  (<a class="graphic graphic_picture graphicRef67988" href="/d/graphic/67988.html" rel="external">picture 2</a>). On histology, PJ polyps are hamartomas that characteristically contain a proliferation of smooth muscle extending into the lamina propria in an arborization-like fashion; the overlying epithelium is normal  (<a class="graphic graphic_picture graphicRef81889 graphicRef69268" href="/d/graphic/81889.html" rel="external">picture 3A-B</a>) [<a href="#rid23">23</a>]. Epithelial misplacement involving all the layers of the bowel has been reported in approximately 10 percent of small intestinal polyps in PJS. Epithelial misplacement, possibly due to mechanical forces, may extend into the serosa and be misdiagnosed as a well-differentiated adenocarcinoma.</p><p class="headingAnchor" id="H435867567"><span class="h2">Cancer risk</span><span class="headingEndMark"> — </span>PJS is associated with an increased risk of gastrointestinal and extra-intestinal malignancies [<a href="#rid24">24-27</a>]. In a systematic review of 20 observational studies which included 1644 patients with PJS, the reported lifetime risk for any cancer varied between 37 and 93 percent [<a href="#rid24">24</a>]. The average age of developing a malignancy was 42 years. The most common sites for malignancy were colorectal, followed by breast, stomach, small bowel, and pancreas.</p><p>In a subsequent report of 133 patients with PJS, the cumulative cancer risk at age 40 and 70 years was 20 and 76 percent, respectively, with a cumulative risk of gastrointestinal cancer of 12 and 51 percent, respectively [<a href="#rid26">26</a>]. The risk of cancer was higher in women as compared with men (hazard ratio 4.8, 95% CI 2.8-8.0). During 5004 person-years of follow-up there were 42 deaths, occurring at a mean age of 45 years. Two-thirds of the deaths were cancer-related. An Italian collaborative study of 119 patients with PJS reported similar rates of cancer [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H435867590"><span class="h3">Gastrointestinal cancers</span><span class="headingEndMark"> — </span>Individuals with PJS have an estimated lifetime risk of gastrointestinal cancer of 38 to 66 percent [<a href="#rid24">24</a>]. The lifetime cancer risk by organ site is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Colorectal – 39 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Stomach – 29 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Small bowel – 13 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Pancreas – 11 to 36 percent</p><p></p><p>Other gastrointestinal tumors that have been associated with PJS include cancers of the biliary tree, gallbladder, and esophagus [<a href="#rid26">26,28,29</a>].</p><p>The distribution of gastrointestinal cancers in PJS is similar to that of the hamartomatous polyps and carcinoma arising in hamartomas has been clearly documented [<a href="#rid30">30-33</a>]. The reason for the increased risk of gastrointestinal cancer is uncertain, but does not appear to be due to increased oncogene expression, known to be involved in the adenoma-carcinoma sequence in colorectal cancer [<a href="#rid34">34</a>]. (See <a class="local">'Epidemiology and genetics'</a> above and  <a class="medical medical_review" href="/d/html/2485.html" rel="external">"Molecular genetics of colorectal cancer"</a>.)</p><p class="headingAnchor" id="H435867596"><span class="h3">Extra-intestinal cancers</span><span class="headingEndMark"> — </span>The risk of extra-intestinal cancers is also increased in individuals with PJS [<a href="#rid35">35,36</a>]. In a meta-analysis of six studies that included 210 individuals with PJS, extracolonic cancers accounted for 55 of the 66 malignancies (83 percent) between the ages of 15 and 64 years [<a href="#rid29">29</a>]. As compared with population-based controls, the risk was increased for cancers of the lung, breast, uterus, and ovary.</p><p class="bulletIndent1"><span class="glyph">●</span>Women with PJS have an increased lifetime risk for cancers of the breast (32 to 54 percent), ovary (21 percent), and cervix (10 percent). Cervical tumors include cervical adenoma malignum, a highly differentiated mucinous adenocarcinoma with a highly aggressive behavior [<a href="#rid37">37</a>]. In addition, small, asymptomatic, benign ovarian tumors known as "sex-cord" tumors with annular tubules (SCTAT tumors) occur commonly in women with PJS [<a href="#rid38">38,39</a>]. These tumors are often associated with signs of hyperestrogenism, which can lead to sexual precocity [<a href="#rid38">38,39</a>]. (See  <a class="medical medical_review" href="/d/html/16833.html" rel="external">"Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Men with PJS have an increased lifetime risk of Sertoli cell testicular tumors (9 percent) [<a href="#rid24">24,36,40</a>]. While these tumors are often hormonally active, some present with gynecomastia, rapid growth, and advanced bone age with markedly elevated levels of estradiol [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/2949.html" rel="external">"Anatomy and pathology of testicular tumors", section on 'Sertoli cell tumors'</a>.)</p><p></p><p class="headingAnchor" id="H435868693"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>A clinical diagnosis of PJS can be made by the presence of any of the following [<a href="#rid42">42</a>]:</p><p class="bulletIndent2"><span class="glyph">•</span>Two or more Peutz-Jeghers-type hamartomatous polyps of the gastrointestinal tract </p><p class="bulletIndent2"><span class="glyph">•</span>Characteristic mucocutaneous hyperpigmentation of the mouth, lips, nose, eyes, genitalia, or fingers in a person with a family history of PJS</p><p class="bulletIndent2"><span class="glyph">•</span>Any number of Peutz-Jeghers polyps in an individual with a family history of PJS in a first-degree relative</p><p class="bulletIndent1"><span class="glyph">●</span>Any number of Peutz-Jeghers polyps in a person with the characteristic mucocutaneous pigmentation of PJS</p><p></p><p>Individuals who meet clinical criteria for PJS should undergo genetic testing for a germline mutation in the <em>STK11</em> gene. Genetic testing in an individual who meets clinical criteria for PJS serves to confirm the diagnosis of PJS and counsel at-risk family members. However, not all mutations associated with PJS have been identified [<a href="#rid9">9</a>]. Thus, if no pathogenic <em>STK11</em> mutation is found in an individual who meets clinical criteria for PJS and there is no known mutation of PJS in the family, this does not exclude the diagnosis of PJS. Such individuals and their at-risk relatives still require frequent endoscopic surveillance for removal of polyps throughout the gastrointestinal tract and screening for extraintestinal cancers. (See <a class="local">'Epidemiology and genetics'</a> above and  <a class="medical medical_review" href="/d/html/15805.html" rel="external">"Juvenile polyposis syndrome", section on 'Screening and management'</a>.)</p><p>If genetic testing is performed and a mutation is found in an affected individual, then genetic testing of at-risk relatives will provide true positive or negative test results. At-risk members who receive true negative test results have a risk of cancer similar to that of the general population. At-risk relatives who test positive should follow the surveillance guidelines for individuals with PJS.</p><p class="headingAnchor" id="H435868640"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Peutz-Jeghers syndrome (PJS) can be differentiated from other disorders that may present with pigmented mucocutaneous macules or multiple hamartomatous gastrointestinal polyps based on the clinical presentation and/or genetic testing.</p><p class="bulletIndent1"><span class="glyph">●</span>Hamartomatous polyps of the small intestine can be associated with Cowden syndrome, Bannayan-Riley Ruvalcaba syndrome (BRRS), and juvenile polyposis syndrome (JPS). BRRS is characterized by macrocephaly, lipomas, vascular abnormalities, and developmental delay. Cowden syndrome has characteristic skin and oral findings including trichilemmomas, acral keratoses, and facial papules/oral papillomas. Pigmented spots in BRRS and Cowden syndrome characteristically occur on the glans penis in males and not on the lips as seen in PJS. Unlike PJS, which is associated with germline mutations in the <em>STK11</em> gene, Cowden syndrome and BRRS are associated with germline mutations in <em>PTEN1</em>.</p><p></p><p class="bulletIndent1">JPS is characterized by multiple gastrointestinal juvenile polyps (hamartomas) but is not associated with mucocutaneous pigmentation, which is associated with PJS. JPS is associated with germline mutations in <em>SMAD4, BMPR1A</em>, and <em>ENG</em> genes and not <em>STK11</em> as seen in patients with PJS. (See  <a class="medical medical_review" href="/d/html/16543.html" rel="external">"PTEN hamartoma tumor syndromes, including Cowden syndrome", section on 'Cowden syndrome'</a> and  <a class="medical medical_review" href="/d/html/16543.html" rel="external">"PTEN hamartoma tumor syndromes, including Cowden syndrome", section on 'Bannayan-Riley-Ruvalcaba syndrome'</a> and  <a class="medical medical_review" href="/d/html/15805.html" rel="external">"Juvenile polyposis syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mucocutaneous pigmentation may be associated with Laugier-Hunziker syndrome (LHS). LHS is an acquired, sporadic, benign disorder that is characterized by intraoral hyperpigmentation on the lips, hard and soft palate, and buccal mucosa. Approximately 60 percent of patients with LHS also have longitudinal hyperpigmented bands on the fingernails and toenails without associated nail dystrophy [<a href="#rid43">43</a>]. Unlike pigmentation in PJS, which occurs in the first few years of life, LHS lesions are progressively acquired in young or middle-age adults. In addition, LHS is not associated with hamartomatous gastrointestinal polyps or a pathogenic mutation in the <em>STK11</em> gene. (See  <a class="medical medical_review" href="/d/html/111807.html" rel="external">"Congenital and inherited hyperpigmentation disorders", section on 'Peutz-Jeghers syndrome'</a>.)</p><p></p><p class="headingAnchor" id="H1034622582"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Guidelines for cancer screening in individuals with Peutz-Jeghers syndrome (PJS) have been proposed by several groups and are largely based on expert opinion and limited observational data [<a href="#rid24">24,36,42,44</a>]. Our recommendations are largely consistent with the guidelines issued by the US Multi-Society Task Force on Colorectal Cancer and the National Comprehensive Cancer Network (NCCN) [<a href="#rid44">44-46</a>].</p><p class="headingAnchor" id="H59298301"><span class="h2">Routine management</span><span class="headingEndMark"> — </span>Individuals with PJS should undergo an annual physical examination with a complete blood count to detect iron deficiency anemia due to occult bleeding from gastrointestinal tract polyps or cancer. (See <a class="local">'Hamartomatous polyps'</a> above and  <a class="medical medical_review" href="/d/html/7150.html" rel="external">"Causes and diagnosis of iron deficiency and iron deficiency anemia in adults", section on 'Causes and risk factors for iron deficiency'</a>.)</p><p class="headingAnchor" id="H1123731161"><span class="h2">Cancer screening</span><span class="headingEndMark"> — </span>Individuals with PJS are at<strong> </strong>an increased risk of gastrointestinal and extraintestinal cancer. The lifetime risk of cancer ranges between 37 and 93 percent, with an average age of 42 years at cancer diagnosis [<a href="#rid24">24</a>]. The most common sites of gastrointestinal tract malignancy are the colon and pancreas, and the most common site of extraintestinal tract cancer is the breast. (See <a class="local">'Clinical manifestations'</a> above.)</p><p class="headingAnchor" id="H2888903126"><span class="h3">Gastrointestinal cancer</span><span class="headingEndMark"> — </span>Due to the increased risk for gastric, small bowel, and colorectal polyps and cancer in individuals with PJS, baseline endoscopic screening of the gastrointestinal tract should include upper gastrointestinal endoscopy (esophagogastroduodenoscopy), video capsule endoscopy (VCE), and colonoscopy, beginning between the ages of eight and ten years [<a href="#rid46">46</a>]. The subsequent screening interval should be based on the findings at baseline examination:</p><p class="bulletIndent1"><span class="glyph">●</span>If polyps are detected on baseline screening, an upper endoscopy, VCE, and colonoscopy should be repeated every two to three years. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If no polyps are detected on baseline screening, an upper endoscopy, VCE, and colonoscopy should be repeated at age 18 years, or sooner if symptoms arise, and then every two to three years.</p><p></p><p>Magnetic resonance enterography (MRE) is an alternative imaging modality for individuals with PJS in whom capsule endoscopy cannot be performed [<a href="#rid47">47</a>]. While neither methodology is associated with ionizing radiation, magnetic resonance imaging (MRI) may be more accurate in identifying and localizing clinically relevant PJS polyps [<a href="#rid48">48</a>]. The use of <a class="drug drug_general" data-topicid="9180" href="/d/drug information/9180.html" rel="external">barium</a> follow-through and computed tomography enterography is limited by radiation exposure and should be avoided in children. (See  <a class="medical medical_review" href="/d/html/2662.html" rel="external">"Wireless video capsule endoscopy", section on 'Contraindications'</a> and  <a class="medical medical_review" href="/d/html/14613.html" rel="external">"Radiation-related risks of imaging", section on 'Children and adolescents'</a>.)</p><p class="headingAnchor" id="H2473085938"><span class="h4">Management of gastrointestinal tract polyps</span><span class="headingEndMark"> — </span>Endoscopic polypectomy should be performed for polyps &gt;0.5 cm that are detected during upper endoscopy and colonoscopy [<a href="#rid46">46</a>]. All other small bowel polyps that are symptomatic or &gt;1 cm in size should be resected in order to reduce the risk of polyp-related complications (eg, anemia, bleeding, obstruction, malignancy, and need for urgent surgery) [<a href="#rid42">42,44</a>]. Advances in small bowel endoscopy have improved the ability to treat small bowel polyps without surgery. Successful small bowel polypectomy using balloon-assisted enteroscopy has been described with both single and double balloon enteroscopies [<a href="#rid48">48,49</a>]. Endoscopists should be aware of possible challenges in performing double balloon enteroscopy in patients who have had previous abdominal surgery and may have peritoneal adhesions and altered anatomy. Patients with PJS may also be at increased risk for perforation with polypectomy due to serosal invagination within the polyp stalk [<a href="#rid49">49</a>].</p><p>Indications for surgery include the inability to achieve endoscopic polyp control either due to polyp size or number and the presence of neoplasia. Surgery may also be required in patients with small bowel obstruction or intussusception. Patients with PJS undergoing laparotomy should undergo intraoperative enteroscopy to identify and resect small bowel polyps [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/d/html/5898.html" rel="external">"Intussusception in children", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/2625.html" rel="external">"Evaluation of suspected small bowel bleeding (formerly obscure gastrointestinal bleeding)", section on 'Intraoperative enteroscopy'</a>.)</p><p class="headingAnchor" id="H974638929"><span class="h4">Chemoprevention</span><span class="headingEndMark"> — </span>Chemopreventive approaches to decrease polyp burden in PJS have been studied, but there are insufficient data to recommend their use [<a href="#rid50">50</a>]. Polyps in PJS overexpress cyclooxygenase-2 (COX-2), suggesting that COX-2 inhibitors may be useful in reducing polyp burden [<a href="#rid51">51</a>]. In addition, inhibition of mammalian target of rapamycin (MTOR) in a PJS mouse model has also been demonstrated to decrease polyp burden [<a href="#rid52">52</a>]. </p><p class="headingAnchor" id="H2120407971"><span class="h3">Genital tract cancers</span></p><p class="headingAnchor" id="H2287065132"><span class="h4">Testicular tumors</span><span class="headingEndMark"> — </span>Patients with PJS are at increased risk for Sertoli cell tumors [<a href="#rid53">53,54</a>]. Annual examinations of the testicles should be performed starting around age 10 years. If abnormalities are detected on testicular examination or if patients have signs of feminization (eg, gynecomastia), additional evaluation (eg, testicular ultrasound) is warranted [<a href="#rid42">42</a>]. (See <a class="local">'Extra-intestinal cancers'</a> above and  <a class="medical medical_review" href="/d/html/2858.html" rel="external">"The pediatric physical examination: The perineum", section on 'Male genitourinary system'</a>.)</p><p class="headingAnchor" id="H989989735"><span class="h4">Cervical cancer</span><span class="headingEndMark"> — </span>Women with PJS are at increased risk for adenoma malignum, a well-differentiated adenocarcinoma of the uterine cervix. We therefore advise women with PJS to undergo annual screening for cervical cancer (including Pap smear) starting at age 18 to 20 years [<a href="#rid44">44,45</a>]. (See <a class="local">'Extra-intestinal cancers'</a> above and  <a class="medical medical_review" href="/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings"</a>.)</p><p class="headingAnchor" id="H1802573239"><span class="h4">Ovarian and endometrial cancer</span><span class="headingEndMark"> — </span>Annual physical examination for observation of precocious puberty should be performed starting at age eight years. We screen women with PJS for endometrial and ovarian cancer with an annual pelvic exam and pap smear starting at age 18 to 20 years [<a href="#rid24">24,42,44</a>]. However, screening for endometrial and ovarian cancer in women with PJS is controversial, and guidelines differ in their recommendations. The NCCN recommends screening with pelvic exam annually between the ages of 18 and 20 years, but other societies also include pelvic ultrasound [<a href="#rid44">44,45</a>]. Other expert guidelines do not recommend screening for endometrial cancer, given that most cases of sporadic endometrial cancer are detected at an early stage, the low risk of endometrial cancer in PJS, and the lack of evidence to support screening [<a href="#rid42">42</a>]. (See <a class="local">'Extra-intestinal cancers'</a> above.)</p><p class="headingAnchor" id="H2623030150"><span class="h3">Breast cancer</span><span class="headingEndMark"> — </span>The risk for breast cancer in PJS patients approaches that of <em>BRCA</em> mutation carriers [<a href="#rid42">42</a>]. We therefore suggest clinical breast examinations for women with PJS every six months and annual breast MRI and mammography starting at age 30 years [<a href="#rid44">44,45</a>]. (See  <a class="medical medical_review" href="/d/html/87311.html" rel="external">"Screening for breast cancer: Evidence for effectiveness and harms", section on 'Effectiveness of imaging studies in breast cancer screening'</a> and <a class="local">'Extra-intestinal cancers'</a> above.) </p><p class="headingAnchor" id="H4247429702"><span class="h3">Pancreatic cancer</span><span class="headingEndMark"> — </span>Screening for pancreatic cancer in individuals with PJS should be performed in experienced centers, preferably within an Institutional Review Board (IRB)-approved clinical research study [<a href="#rid42">42,55</a>]. Screening for pancreatic cancer should be performed with MRI/magnetic resonance cholangiopancreatography or endoscopic ultrasound of the pancreas every one to two years, beginning at age 35 years [<a href="#rid44">44-46,56,57</a>]. (See <a class="local">'Gastrointestinal cancers'</a> above and  <a class="medical medical_review" href="/d/html/83943.html" rel="external">"Familial risk factors for pancreatic cancer and screening of high-risk patients", section on 'Pancreatic cancer screening'</a>.)</p><p class="headingAnchor" id="H810519458"><span class="h3">Other malignancies</span><span class="headingEndMark"> — </span>Individuals with PJS are also at an increased risk for thyroid and lung cancer. However, evidence to support routine screening for these cancers in the absence of other risk factors is lacking. Patients should seek medical attention for evaluation of new symptoms and should be strongly counselled to quit smoking [<a href="#rid36">36,42,44</a>]. (See  <a class="medical medical_review" href="/d/html/7059.html" rel="external">"Radiation-induced thyroid disease"</a> and  <a class="medical medical_review" href="/d/html/7566.html" rel="external">"Screening for lung cancer"</a>.)</p><p class="headingAnchor" id="H3728006042"><span class="h2">Other issues</span></p><p class="headingAnchor" id="H4794981"><span class="h3">Cutaneous hyperpigmentation</span><span class="headingEndMark"> — </span>Approximately 95 percent of PJS patients develop mucocutaneous pigmented macules. While most cutaneous lesions fade with age, lesions that are disfiguring or associated with psychological morbidity may require treatment [<a href="#rid42">42,58-61</a>]. The management of cutaneous hyperpigmentation is discussed in detail, separately. (See  <a class="medical medical_review" href="/d/html/89268.html" rel="external">"Acquired hyperpigmentation disorders", section on 'General principles of treatment'</a> and  <a class="medical medical_review" href="/d/html/111807.html" rel="external">"Congenital and inherited hyperpigmentation disorders", section on 'Peutz-Jeghers syndrome'</a>.)</p><p class="headingAnchor" id="H3732021766"><span class="h3">Genetic counseling</span><span class="headingEndMark"> — </span>PJS is an autosomal dominant disorder, and a child of a PJS parent has a 50 percent chance of inheriting the disease. Individuals with an <em>STK11</em> mutation should be offered the option of a pre-implantation genetic diagnosis during preconception counseling [<a href="#rid62">62-64</a>]. However, patients should also be made aware of the limitations and the risks for misdiagnosis. (See  <a class="medical medical_review" href="/d/html/6783.html" rel="external">"Preimplantation genetic testing", section on 'Genetic analysis'</a>.)</p><p>First-degree relatives of patients with PJS should be screened annually, beginning at birth, for clinical features of PJS. Screening consists of a history and a physical examination that includes evaluation for mucocutaneous pigmentation and signs of precocious puberty. In addition, male patients should be examined for signs of feminization (eg, gynecomastia) and for testicular tumors with testicular palpation. Predictive genetic testing should be offered to at-risk individuals in whom the diagnosis is not already clinically apparent by eight years of age, provided a pathogenic <em>STK11</em> mutation has been identified in an affected family member. The results of genetic testing can then guide future screening recommendations. (See  <a class="medical medical_review" href="/d/html/5812.html" rel="external">"Definition, etiology, and evaluation of precocious puberty", section on 'Definition'</a> and  <a class="medical medical_review" href="/d/html/2901.html" rel="external">"Genetic testing", section on 'Testing children'</a> and  <a class="medical medical_review" href="/d/html/2858.html" rel="external">"The pediatric physical examination: The perineum", section on 'Male genitourinary system'</a>.)</p><p class="headingAnchor" id="H1623647421"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113838.html" rel="external">"Society guideline links: Hereditary colorectal cancer syndromes"</a>.) </p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and genetics</strong> – Peutz-Jeghers syndrome (PJS) is an autosomal dominant syndrome characterized by multiple hamartomatous polyps in the gastrointestinal tract, mucocutaneous pigmentation, and an increased risk of gastrointestinal and extra-intestinal cancer. </p><p></p><p class="bulletIndent1">PJS is associated with germline mutations in t<em>he STK11 (LKB1) </em>g<em>e</em>ne<em> </em>encoding a serine threonine kinase mapped to chromosome 19p13.3. PJS is rare, with prevalence estimates ranging between 1:8000 and 1:200,000 births. (See <a class="local">'Epidemiology and genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – There are two main clinical manifestations of PJS: pigmented mucocutaneous macules and multiple gastrointestinal polyps. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The characteristic mucocutaneous pigmentations (melanin spots) of PJS are present in more than 95 percent of patients, occurring most commonly on the lips and perioral region, palms of the hands, buccal mucosa, and soles of the feet.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastrointestinal hamartomatous polyps are present in most patients with PJS and can occur anywhere in the gastrointestinal tract. Polyps develop in the first decade of life and most patients become symptomatic between the age of 10 and 30 years. The number of polyps ranges from 1 to more than 20 per segment of bowel.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cancer risk</strong> – PJS is associated with an increased risk of gastrointestinal and extra-intestinal cancers. The lifetime risk of cancer ranges between 37 and 93 percent, with an average age of 42 years at cancer diagnosis. The most common sites of gastrointestinal tract malignancy are the colon and pancreas, and the most common site of extraintestinal tract cancer is the breast. Women are also at increased risk for cervical tumors including cervical adenoma malignum and benign ovarian tumors known as "sex-cord" tumors with annular tubules (SCTAT tumors). Men with PJS have an increased lifetime risk of Sertoli cell testicular tumors. (See <a class="local">'Cancer risk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– A clinical diagnosis of PJS can be made by the presence of any of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two or more Peutz-Jeghers-type hamartomatous polyps of the gastrointestinal tract </p><p class="bulletIndent2"><span class="glyph">•</span>Characteristic mucocutaneous hyperpigmentation of the mouth, lips, nose, eyes, genitalia, or fingers in a person with a family history of PJS</p><p class="bulletIndent2"><span class="glyph">•</span>Any number of Peutz-Jeghers polyps in an individual with a family history of PJS in a first-degree relative</p><p class="bulletIndent1"><span class="glyph">●</span>Any number of Peutz-Jeghers polyps in a person with the characteristic mucocutaneous pigmentation of PJS</p><p></p><p class="bulletIndent1">Individuals who meet clinical criteria for PJS should undergo genetic testing for a mutation in t<em>he STK11</em> gene. Genetic testing in an individual who meets clinical criteria for PJS serves to confirm the diagnosis of PJS. However, the absence of a pathogen<em>ic STK11</em> mutation in an individual who meets clinical criteria for PJS does not exclude the diagnosis of PJS. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">PJS can be differentiated from other disorders with pigmented mucocutaneous macules or multiple hamartomatous gastrointestinal polyps based on the clinical manifestations and/or genetic testing. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Our approach to cancer screening in individuals with PJS is as follows (see <a class="local">'Routine management'</a> above and <a class="local">'Cancer screening'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Annual physical examination with a complete blood count to detect iron deficiency anemia due to occult bleeding from gastrointestinal tract polyps or cancer.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Baseline screening of the stomach and colon with upper endoscopy and colonoscopy every two to three years beginning in the late teens.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Baseline endoscopic screening of the small intestine with video capsule endoscopy (VCE) between age eight and ten years. The interval for follow-up is based on the findings. However, in the absence of polyps, follow-up screening is recommended at 18 years and then repeated every two to three years. Computed tomography enterography (CTE) or magnetic resonance enterography (MRE) are alternative imaging modalities for individuals with PJS in whom capsule endoscopy cannot be performed. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Annual examination of the testicles from age 10 years. If abnormalities are detected on testicular examination or if patients have signs of feminization (eg, gynecomastia), a testicular ultrasound should be obtained.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Annual pelvic examination and Pap smear starting at age 18 to 20 years in women.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monthly breast self-examinations and clinical breast exams every six months for women and annual breast magnetic resonance imaging (MRI) and mammography starting at age 30 years.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>MRI/magnetic resonance cholangiopancreatography or endoscopic ultrasound of the pancreas every one to two years, beginning at age 35 years, to screen for pancreatic cancer. Screening for pancreatic cancer should be performed at centers of expertise in the setting of a research protocol.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with an <em>STK11</em> mutation should be offered the option of a pre-implantation genetic diagnosis during preconception counseling. First-degree relatives of patients with PJS should be screened beginning at birth for clinical features of PJS. Screening consists of an annual history, a physical examination that includes evaluation for mucocutaneous pigmentation, and signs of precocious puberty. In addition, male patients should be examined for signs of feminization (eg, gynecomastia) and for testicular tumors with testicular palpation. Predictive genetic testing should be offered to at-risk individuals in whom the diagnosis is not already clinically apparent by age eight years, provided a pathogenic <em>STK11</em> mutation has been identified in an affected family member. (See <a class="local">'Genetic counseling'</a> above.)</p><p></p><p class="headingAnchor" id="H766583831"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff thank Dr. Anthony J Lembo, MD, for his contributions as author to prior versions of this topic review.</p><p>The UpToDate editorial staff also acknowledges Paul Rutgeerts, MD (deceased), who contributed to earlier versions of this topic review and was a section editor for UpToDate in Gastroenterology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">JEGHERS H, McKUSICK VA, KATZ KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance. N Engl J Med 1949; 241:1031.</a></li><li><a class="nounderline abstract_t">Peutz JL. Over een zeer merkwaardige, gecombineerde familiaire pollyposis van de sligmliezen van den tractus intestinalis met die van de neuskeelholte en gepaard met eigenaardige pigmentaties van huid-en slijmvliezen. Ned Maandschr v Gen 1921; 10:134.</a></li><li><a class="nounderline abstract_t">JEGHERS H, McKUSICK VA, KATZ KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance. N Engl J Med 1949; 241:993, illust; passim.</a></li><li><a class="nounderline abstract_t">Harned RK, Buck JL, Sobin LH. The hamartomatous polyposis syndromes: clinical and radiologic features. AJR Am J Roentgenol 1995; 164:565.</a></li><li><a class="nounderline abstract_t">Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 1998; 90:1039.</a></li><li><a class="nounderline abstract_t">Olschwang S, Markie D, Seal S, et al. Peutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3. J Med Genet 1998; 35:42.</a></li><li><a class="nounderline abstract_t">Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998; 18:38.</a></li><li><a class="nounderline abstract_t">Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998; 391:184.</a></li><li><a class="nounderline abstract_t">Lim W, Hearle N, Shah B, et al. Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome. Br J Cancer 2003; 89:308.</a></li><li><a class="nounderline abstract_t">Boudeau J, Sapkota G, Alessi DR. LKB1, a protein kinase regulating cell proliferation and polarity. FEBS Lett 2003; 546:159.</a></li><li><a class="nounderline abstract_t">Hernan I, Roig I, Martin B, et al. De novo germline mutation in the serine-threonine kinase STK11/LKB1 gene associated with Peutz-Jeghers syndrome. Clin Genet 2004; 66:58.</a></li><li><a class="nounderline abstract_t">Kullmann L, Krahn MP. Controlling the master-upstream regulation of the tumor suppressor LKB1. Oncogene 2018; 37:3045.</a></li><li><a class="nounderline abstract_t">Poffenberger MC, Metcalfe-Roach A, Aguilar E, et al. LKB1 deficiency in T cells promotes the development of gastrointestinal polyposis. Science 2018; 361:406.</a></li><li><a class="nounderline abstract_t">Volikos E, Robinson J, Aittomäki K, et al. LKB1 exonic and whole gene deletions are a common cause of Peutz-Jeghers syndrome. J Med Genet 2006; 43:e18.</a></li><li><a class="nounderline abstract_t">Mehenni H, Gehrig C, Nezu J, et al. Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity. Am J Hum Genet 1998; 63:1641.</a></li><li><a class="nounderline abstract_t">Hearle N, Lucassen A, Wang R, et al. Mapping of a translocation breakpoint in a Peutz-Jeghers hamartoma to the putative PJS locus at 19q13.4 and mutation analysis of candidate genes in polyp and STK11-negative PJS cases. Genes Chromosomes Cancer 2004; 41:163.</a></li><li><a class="nounderline abstract_t">Wang HH, Xie NN, Li QY, et al. Exome sequencing revealed novel germline mutations in Chinese Peutz-Jeghers syndrome patients. Dig Dis Sci 2014; 59:64.</a></li><li><a class="nounderline abstract_t">Utsunomiya J, Gocho H, Miyanaga T, et al. Peutz-Jeghers syndrome: its natural course and management. Johns Hopkins Med J 1975; 136:71.</a></li><li><a class="nounderline abstract_t">Hinds R, Philp C, Hyer W, Fell JM. Complications of childhood Peutz-Jeghers syndrome: implications for pediatric screening. J Pediatr Gastroenterol Nutr 2004; 39:219.</a></li><li><a class="nounderline abstract_t">van Lier MG, Mathus-Vliegen EM, Wagner A, et al. High cumulative risk of intussusception in patients with Peutz-Jeghers syndrome: time to update surveillance guidelines? Am J Gastroenterol 2011; 106:940.</a></li><li><a class="nounderline abstract_t">Cunningham JD, Vine AJ, Karch L, Aisenberg J. The role of laparoscopy in the management of intussusception in the Peutz-Jeghers syndrome: case report and review of the literature. Surg Laparosc Endosc 1998; 8:17.</a></li><li><a class="nounderline abstract_t">Duan SX, Wang GH, Zhong J, et al. Peutz-Jeghers syndrome with intermittent upper intestinal obstruction: A case report and review of the literature. Medicine (Baltimore) 2017; 96:e6538.</a></li><li><a class="nounderline abstract_t">Haggitt RC, Reid BJ. Hereditary gastrointestinal polyposis syndromes. Am J Surg Pathol 1986; 10:871.</a></li><li><a class="nounderline abstract_t">van Lier MG, Wagner A, Mathus-Vliegen EM, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 2010; 105:1258.</a></li><li><a class="nounderline abstract_t">Lim W, Olschwang S, Keller JJ, et al. Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology 2004; 126:1788.</a></li><li><a class="nounderline abstract_t">van Lier MG, Westerman AM, Wagner A, et al. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut 2011; 60:141.</a></li><li><a class="nounderline abstract_t">Resta N, Pierannunzio D, Lenato GM, et al. Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study. Dig Liver Dis 2013; 45:606.</a></li><li><a class="nounderline abstract_t">Rebsdorf Pedersen I, Hartvigsen A, Fischer Hansen B, et al. Management of Peutz-Jeghers syndrome. Experience with patients from the Danish Polyposis Register. Int J Colorectal Dis 1994; 9:177.</a></li><li><a class="nounderline abstract_t">Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119:1447.</a></li><li><a class="nounderline abstract_t">Perzin KH, Bridge MF. Adenomatous and carcinomatous changes in hamartomatous polyps of the small intestine (Peutz-Jeghers syndrome): report of a case and review of the literature. Cancer 1982; 49:971.</a></li><li><a class="nounderline abstract_t">Settaf A, Mansori F, Bargach S, Saidi A. [Peutz-Jeghers syndrome with carcinomatous degeneration of a duodenal hamartomatous polyp]. Ann Gastroenterol Hepatol (Paris) 1990; 26:285.</a></li><li><a class="nounderline abstract_t">Defago MR, Higa AL, Campra JL, et al. Carcinoma in situ arising in a gastric hamartomatous polyp in a patient with Peutz-Jeghers syndrome. Endoscopy 1996; 28:267.</a></li><li><a class="nounderline abstract_t">Bujanda L, Beguiristain A, Villar JM, et al. [Gastric adenocarcinoma in hamartomatous polyp in Peutz-Jeghers syndrome]. Gastroenterol Hepatol 1996; 19:452.</a></li><li><a class="nounderline abstract_t">Entius MM, Westerman AM, Giardiello FM, et al. Peutz-Jeghers polyps, dysplasia, and K-ras codon 12 mutations. Gut 1997; 41:320.</a></li><li><a class="nounderline abstract_t">Giardiello FM, Welsh SB, Hamilton SR, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 1987; 316:1511.</a></li><li><a class="nounderline abstract_t">Boardman LA, Thibodeau SN, Schaid DJ, et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med 1998; 128:896.</a></li><li><a class="nounderline abstract_t">Srivatsa PJ, Keeney GL, Podratz KC. Disseminated cervical adenoma malignum and bilateral ovarian sex cord tumors with annular tubules associated with Peutz-Jeghers syndrome. Gynecol Oncol 1994; 53:256.</a></li><li><a class="nounderline abstract_t">Young RH, Dickersin GR, Scully RE. A distinctive ovarian sex cord-stromal tumor causing sexual precocity in the Peutz-Jeghers syndrome. Am J Surg Pathol 1983; 7:233.</a></li><li><a class="nounderline abstract_t">Young RH, Welch WR, Dickersin GR, Scully RE. Ovarian sex cord tumor with annular tubules: review of 74 cases including 27 with Peutz-Jeghers syndrome and four with adenoma malignum of the cervix. Cancer 1982; 50:1384.</a></li><li><a class="nounderline abstract_t">Wilson DM, Pitts WC, Hintz RL, Rosenfeld RG. Testicular tumors with Peutz-Jeghers syndrome. Cancer 1986; 57:2238.</a></li><li><a class="nounderline abstract_t">Young S, Gooneratne S, Straus FH 2nd, et al. Feminizing Sertoli cell tumors in boys with Peutz-Jeghers syndrome. Am J Surg Pathol 1995; 19:50.</a></li><li><a class="nounderline abstract_t">Beggs AD, Latchford AR, Vasen HF, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 2010; 59:975.</a></li><li><a class="nounderline abstract_t">Kemmett D, Ellis J, Spencer MJ, Hunter JA. The Laugier-Hunziker syndrome--a clinical review of six cases. Clin Exp Dermatol 1990; 15:111.</a></li><li><a class="nounderline abstract_t">Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015; 110:223.</a></li><li class="breakAll">National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment: Colorectal. Version 1.2020. www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf.</li><li><a class="nounderline abstract_t">Boland CR, Idos GE, Durno C, et al. Diagnosis and Management of Cancer Risk in the Gastrointestinal Hamartomatous Polyposis Syndromes: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2022; 162:2063.</a></li><li><a class="nounderline abstract_t">Gupta A, Postgate AJ, Burling D, et al. A prospective study of MR enterography versus capsule endoscopy for the surveillance of adult patients with Peutz-Jeghers syndrome. AJR Am J Roentgenol 2010; 195:108.</a></li><li><a class="nounderline abstract_t">Tomas C, Soyer P, Dohan A, et al. Update on imaging of Peutz-Jeghers syndrome. World J Gastroenterol 2014; 20:10864.</a></li><li><a class="nounderline abstract_t">Korsse SE, Dewint P, Kuipers EJ, van Leerdam ME. Small bowel endoscopy and Peutz-Jeghers syndrome. Best Pract Res Clin Gastroenterol 2012; 26:263.</a></li><li><a class="nounderline abstract_t">Kuwada SK, Burt R. A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome. Fam Cancer 2011; 10:469.</a></li><li><a class="nounderline abstract_t">Udd L, Katajisto P, Rossi DJ, et al. Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2. Gastroenterology 2004; 127:1030.</a></li><li><a class="nounderline abstract_t">Wei C, Amos CI, Zhang N, et al. Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling. Clin Cancer Res 2008; 14:1167.</a></li><li><a class="nounderline abstract_t">Giardiello FM, Trimbath JD. Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 2006; 4:408.</a></li><li><a class="nounderline abstract_t">Dreyer L, Jacyk WK, du Plessis DJ. Bilateral large-cell calcifying Sertoli cell tumor of the testes with Peutz-Jeghers syndrome: a case report. Pediatr Dermatol 1994; 11:335.</a></li><li><a class="nounderline abstract_t">Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62:339.</a></li><li><a class="nounderline abstract_t">Goggins M, Overbeek KA, Brand R, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020; 69:7.</a></li><li><a class="nounderline abstract_t">Aslanian HR, Lee JH, Canto MI. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review. Gastroenterology 2020; 159:358.</a></li><li><a class="nounderline abstract_t">Li Y, Tong X, Yang J, et al. Q-switched alexandrite laser treatment of facial and labial lentigines associated with Peutz-Jeghers syndrome. Photodermatol Photoimmunol Photomed 2012; 28:196.</a></li><li><a class="nounderline abstract_t">Xi Z, Hui Q, Zhong L. Q-switched alexandrite laser treatment of oral labial lentigines in Chinese subjects with Peutz-Jeghers syndrome. Dermatol Surg 2009; 35:1084.</a></li><li><a class="nounderline abstract_t">Chang CJ, Nelson JS. Q-switched ruby laser treatment of mucocutaneous melanosis associated with Peutz-Jeghers syndrome. Ann Plast Surg 1996; 36:394.</a></li><li><a class="nounderline abstract_t">Benedict LM, Cohen B. Treatment of Peutz-Jeghers lentigines with the carbon dioxide laser. J Dermatol Surg Oncol 1991; 17:954.</a></li><li><a class="nounderline abstract_t">Practice Committee of the Society for Assisted Reproductive Technology, Practice Committee of the American Society for Reproductive Medicine. Preimplantation genetic testing: a Practice Committee opinion. Fertil Steril 2007; 88:1497.</a></li><li><a class="nounderline abstract_t">van Lier MG, Korsse SE, Mathus-Vliegen EM, et al. Peutz-Jeghers syndrome and family planning: the attitude towards prenatal diagnosis and pre-implantation genetic diagnosis. Eur J Hum Genet 2012; 20:236.</a></li><li><a class="nounderline abstract_t">Woo A, Sadana A, Mauger DT, et al. Psychosocial impact of Peutz-Jeghers Syndrome. Fam Cancer 2009; 8:59.</a></li></ol></div><div id="topicVersionRevision">Topic 2533 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15398245" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Over een zeer merkwaardige, gecombineerde familiaire pollyposis van de sligmliezen van den tractus intestinalis met die van de neuskeelholte en gepaard met eigenaardige pigmentaties van huid-en slijmvliezen</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15399020" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7863873" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The hamartomatous polyposis syndromes: clinical and radiologic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9672254" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The concise handbook of family cancer syndromes. Mayo Familial Cancer Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9475093" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Peutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9425897" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9428765" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A serine/threonine kinase gene defective in Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12865922" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12829253" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : LKB1, a protein kinase regulating cell proliferation and polarity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15200509" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : De novo germline mutation in the serine-threonine kinase STK11/LKB1 gene associated with Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29540834" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Controlling the master-upstream regulation of the tumor suppressor LKB1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30049881" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : LKB1 deficiency in T cells promotes the development of gastrointestinal polyposis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16648371" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : LKB1 exonic and whole gene deletions are a common cause of Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9837816" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15287029" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mapping of a translocation breakpoint in a Peutz-Jeghers hamartoma to the putative PJS locus at 19q13.4 and mutation analysis of candidate genes in polyp and STK11-negative PJS cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24154639" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Exome sequencing revealed novel germline mutations in Chinese Peutz-Jeghers syndrome patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1117595" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Peutz-Jeghers syndrome: its natural course and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15269641" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Complications of childhood Peutz-Jeghers syndrome: implications for pediatric screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21157440" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : High cumulative risk of intussusception in patients with Peutz-Jeghers syndrome: time to update surveillance guidelines?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9488564" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The role of laparoscopy in the management of intussusception in the Peutz-Jeghers syndrome: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28445255" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Peutz-Jeghers syndrome with intermittent upper intestinal obstruction: A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3024515" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hereditary gastrointestinal polyposis syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20051941" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15188174" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Relative frequency and morphology of cancers in STK11 mutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21205875" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23415580" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7876718" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Management of Peutz-Jeghers syndrome. Experience with patients from the Danish Polyposis Register.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11113065" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Very high risk of cancer in familial Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7059931" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Adenomatous and carcinomatous changes in hamartomatous polyps of the small intestine (Peutz-Jeghers syndrome): report of a case and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2082804" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : [Peutz-Jeghers syndrome with carcinomatous degeneration of a duodenal hamartomatous polyp].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8739752" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Carcinoma in situ arising in a gastric hamartomatous polyp in a patient with Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8998668" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : [Gastric adenocarcinoma in hamartomatous polyp in Peutz-Jeghers syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9378385" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Peutz-Jeghers polyps, dysplasia, and K-ras codon 12 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3587280" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Increased risk of cancer in the Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9634427" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Increased risk for cancer in patients with the Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8188091" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Disseminated cervical adenoma malignum and bilateral ovarian sex cord tumors with annular tubules associated with Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6837833" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A distinctive ovarian sex cord-stromal tumor causing sexual precocity in the Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7104978" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Ovarian sex cord tumor with annular tubules: review of 74 cases including 27 with Peutz-Jeghers syndrome and four with adenoma malignum of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3697923" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Testicular tumors with Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7802138" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Feminizing Sertoli cell tumors in boys with Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20581245" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Peutz-Jeghers syndrome: a systematic review and recommendations for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2347100" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The Laugier-Hunziker syndrome--a clinical review of six cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25645574" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25645574" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35487791" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Diagnosis and Management of Cancer Risk in the Gastrointestinal Hamartomatous Polyposis Syndromes: Recommendations From the US Multi-Society Task Force on Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20566803" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A prospective study of MR enterography versus capsule endoscopy for the surveillance of adult patients with Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25152588" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Update on imaging of Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22704569" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Small bowel endoscopy and Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21826537" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15480979" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Suppression of Peutz-Jeghers polyposis by inhibition of cyclooxygenase-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18281551" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16616343" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Peutz-Jeghers syndrome and management recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7899185" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Bilateral large-cell calcifying Sertoli cell tumor of the testes with Peutz-Jeghers syndrome: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23135763" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31672839" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32416142" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23017172" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Q-switched alexandrite laser treatment of facial and labial lentigines associated with Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438690" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Q-switched alexandrite laser treatment of oral labial lentigines in Chinese subjects with Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8728583" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Q-switched ruby laser treatment of mucocutaneous melanosis associated with Peutz-Jeghers syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1960267" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Treatment of Peutz-Jeghers lentigines with the carbon dioxide laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17945219" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Preimplantation genetic testing: a Practice Committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21829227" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Peutz-Jeghers syndrome and family planning: the attitude towards prenatal diagnosis and pre-implantation genetic diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18604594" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Psychosocial impact of Peutz-Jeghers Syndrome.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
